Insights Into Prostate Cancer 2025

Gain perspectives on the use of androgen receptor inhibitors and radioligand therapies in the management of mHSPC and mCRPC and how evolving clinical data may influence treatment decisions.

Midwest September 13, 2025
Purchase Report

FACULTY CHAIR

Ulka Vaisshampayan, MD

University of Michigan, Ann Arbor, MI, USA

MORE INFORMATION

  • Chicago, IL
  • Illinois, Indiana, Minnesota, Nebraska, Ohio, South Dakota, Wisconsin

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • Explore use/barriers to use of AR inhibitors for management of mHSPC
  • Explore use/barriers to use of radioligand therapy for management of mCRPC
  • Examine perceptions of evolving clinical data and their impact on therapy choice in mHSPC and mCRPC

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection was accomplished through the use of audience response system questioning and moderated discussion
  • The group of advisors comprises 15 community oncologist from the Midwest region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.